Kyverna Therapeutics
KYTX
79 hedge funds and large institutions have $71.4M invested in Kyverna Therapeutics in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 24 closing their positions.
43% more capital invested
Capital invested by funds: $50M → $71.4M (+$21.4M)
21% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 24
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6.02% less ownership
Funds ownership: 59.71% → 53.7% (-6%)
9% less funds holding
Funds holding: 87 → 79 (-8)
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.09M |
| 2 |
Millennium Management
New York
|
+$530K |
| 3 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$401K |
| 4 |
Jane Street
New York
|
+$217K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$197K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$3.57M |
| 2 |
BlackRock
New York
|
-$2.83M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.65M |
| 4 |
State Street
Boston,
Massachusetts
|
-$701K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$684K |
KYTX Hedge Fund Activity: Q2 2025 in Review
79 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q2 2025, worth a combined $71.4M — up 43% from $50M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of KYTX and 16 opened new positions — a net loss of 8 holders — while 24 trimmed existing stakes and 29 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $3.09M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $3.57M sold.
- 79 institutional investors held Kyverna Therapeutics (KYTX) as of Q2 2025, down from 87 in Q1 2025.
- Funds reported $71.4M of Kyverna Therapeutics stock for Q2 2025, up 43% quarter-over-quarter.
- 16 funds opened new Kyverna Therapeutics positions in Q2 2025 and 24 closed out, a net change of -8 holders.
- The largest Kyverna Therapeutics buyer in Q2 2025 was T. Rowe Price Associates, an estimated $3.09M added.
- The largest Kyverna Therapeutics seller in Q2 2025 was Novo Holdings A/S, an estimated $3.57M sold.
Based on aggregated 13F filings for Q2 2025.